Algert Global LLC Sells 8,854 Shares of Zafgen Inc (ZFGN)

Algert Global LLC cut its position in shares of Zafgen Inc (NASDAQ:ZFGN) by 12.0% in the fourth quarter, HoldingsChannel reports. The firm owned 65,101 shares of the biopharmaceutical company’s stock after selling 8,854 shares during the period. Algert Global LLC’s holdings in Zafgen were worth $322,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. First Manhattan Co. purchased a new stake in shares of Zafgen during the 4th quarter worth about $27,000. Meeder Asset Management Inc. raised its stake in shares of Zafgen by 547.1% during the 4th quarter. Meeder Asset Management Inc. now owns 9,118 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 7,709 shares in the last quarter. Voya Investment Management LLC purchased a new stake in shares of Zafgen during the 2nd quarter worth about $104,000. Wells Fargo & Company MN raised its stake in shares of Zafgen by 428.7% during the 3rd quarter. Wells Fargo & Company MN now owns 14,783 shares of the biopharmaceutical company’s stock worth $173,000 after purchasing an additional 11,987 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Zafgen by 36.0% during the 3rd quarter. American International Group Inc. now owns 20,222 shares of the biopharmaceutical company’s stock worth $236,000 after purchasing an additional 5,351 shares in the last quarter. 81.95% of the stock is owned by institutional investors.

Get Zafgen alerts:

Shares of ZFGN stock opened at $4.80 on Monday. The company has a current ratio of 11.78, a quick ratio of 11.78 and a debt-to-equity ratio of 0.16. Zafgen Inc has a twelve month low of $4.10 and a twelve month high of $12.35. The company has a market capitalization of $176.98 million, a P/E ratio of -2.53 and a beta of -0.36.

ZFGN has been the subject of a number of recent research reports. Leerink Swann raised Zafgen from a “market perform” rating to an “outperform” rating and set a $4.52 price target for the company in a research note on Thursday. Zacks Investment Research raised Zafgen from a “hold” rating to a “buy” rating and set a $5.75 price objective on the stock in a research note on Tuesday, December 4th. BidaskClub downgraded Zafgen from a “buy” rating to a “hold” rating in a research note on Thursday, November 22nd. Svb Leerink raised Zafgen from a “market perform” rating to an “outperform” rating in a research note on Thursday. Finally, ValuEngine raised Zafgen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Four equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $12.45.

COPYRIGHT VIOLATION NOTICE: “Algert Global LLC Sells 8,854 Shares of Zafgen Inc (ZFGN)” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/4142525/algert-global-llc-sells-8854-shares-of-zafgen-inc-zfgn.html.

Zafgen Company Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

Featured Story: What is Cost of Debt?

Want to see what other hedge funds are holding ZFGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zafgen Inc (NASDAQ:ZFGN).